Search PubMed⌕ Search

Biomedical subjects

B C Mehta

Publications and source records attributed to B C Mehta.

At least 37 records · Page 2Linked to original sources
PubMed1993

Effect of iron deficiency anaemia and its treatment on single dose phenytoin bioavailability.

Iron deficiency is a common nutritional deficiency, which leads to structural functional and enzymatic changes in the body that may affect the pharmacokinetics of drugs. The present study in 7 normal volunteers and 8 adult male patients with iron deficiency anaemia (IDA) was done to investigate the effect of iron deficiency and its treatment with total dose iron (TDI) on the bioavailability of a single dose of phenytoin. Phenytoin bioavailability was investigated before and 3 and 28 days after TDI. The bioavailability parameters Cmax, tmax, AUC and 2 h phenytoin concentrations were not significantly different in anaemic patients as compared to normal volunteers before or after treatment, except for an increase in tmax 28 days after TDI treatment.

Adult↗
PubMed1993

Autoantibodies in thalassaemia major: relationship with oral iron chelator L1.

Ninety patients with thalassaemia major were investigated for the occurrence of antinuclear antibodies (ANA), and those with ANA were tested for antibodies to histones (AHA). ANA were detected in 7 of 27 thalassemics on oral iron chelator L1, and in 2 of 63 thalassaemics not on L1 (p < 0.01). AHA were seen in 4 of 7 thalassemics receiving L1 with positive ANA, and in none of the 2 not receiving L1 (p < 0.03). Joint pains were seen in patients receiving L1, but in none of the patients not receiving L1. There was no correlation between hepatitis B or HIV positivity and presence of ANA or joint pains. While some amount of background ANA-positivity was found in patients with thalassaemia major, it was significantly more in patients receiving L1. Laboratory evidence of drug-induced lupus-like reaction was seen only in patients who received L1. In view of serious concerns about the safety of L1 and wide variations in the incidence and severity of adverse reactions reported by different sources, an urgent regulatory audit of all trial centres is essential.

Adolescent↗
PubMed1992

A randomized placebo-controlled double-blind study of danazol in hemophilia A.

A randomized double-blind placebo-controlled crossover trial of danazol was carried out in 19 cases of hemophilia A. Danazol was given for 3 months at a dose of 150 mg/day to patients under 15 years of age, and 300 mg/day to older patients. The basal factor VIII:C level was 8.3 +/- 5.6% (mean +/- SD), and after 3 months of danazol treatment was 15.3 +/- 11.0% (p = 0.02). Six patients (basal factor VIII:C 2-22%) showed a 1.36- to 2.87-fold elevation of factor VIII:C levels after danazol. 0/2, 1/4 and 5/13 cases of severe, moderate and mild disease, respectively, responded. Decreases in the number of bleeding episodes and cryoprecipitate requirement were seen in the responders. No adverse reactions to danazol were encountered. Danazol appears to raise the factor VIII:C levels in selected cases of hemophilia A.

Adolescent↗
PubMed1992

Aplastic crisis and leg ulceration: two rare complications of hereditary sideroblastic anaemia.

Aplastic crisis as a result of parvovirus infection is seen in a number of haematologic disorders characterized by decreased red cell survival, and leg ulceration due to unknown causes is seen in a number of haemolytic anaemias. Neither of the two has been reported in a case of sideroblastic anemia. We report one case with each of these complications in association with sideroblastic anaemia.

Adult↗
PubMed1992

Intravenous immunoglobulin therapy of immune thrombocytopenia.

High dose intravenous gamma globulin has been used in the therapy of immune thrombocytopenia with variable success. Nine non-splenectomized patients with immune thrombocytopenia (8 ITP, 1 Evans syndrome) were treated with IV IgG. One patient with ITP and the case of Evans syndrome had chronic disease, and the others had acute ITP. All patients had been pretreated with steroids with variable response. The patient with chronic ITP and the one with Evans syndrome responded completely to IgG; remission has lasted for 18 months in both. Two patients with acute ITP responded fully to IgG, but one relapsed after 8 months and the other was lost to follow-up after 1 month. Two patients with acute ITP had partial response to IgG, which could be maintained off steroids in one and on a low dose of steroids in the other. Three patients with acute ITP had no response at all to IgG. High dose IV IgG is useful in selected cases of acute as well as chronic ITP, and previous response to steroids increases the likelihood of response. Splenectomy is not a prerequisite for response.

Adolescent↗
PubMed1992

Factor VII inhibitor.

Acquired inhibitors of blood coagulation factors occur spontaneously or secondarily to various diseases or drug administration. A clinically significant factor VII inhibitor is very rare. We report a patient developing factor VII inhibitor possibly as a reaction to penicillin administration; it gave rise to fatal haemorrhage.

Factor VII↗
PubMed1992

Hereditary spherocytosis: experience of 145 cases.

145 patients were diagnosed to have hereditary spherocytosis (HS) over a period of 25 years. Jaundice (66.9%), fever (65.5%), weakness (44.8%), and abdominal pain (35.8%) were the commonest complaints. 94.5% had splenomegaly (JP-17 cm) and 71.7% had hepatomegaly (JP-6 cm). Spherocytes were detected in the peripheral smears of all patients at presentation on careful examination. 67 patients had been investigated elsewhere and spherocytes missed in 86.6%. Gall stones were seen in 20 of the 54 patients investigated. Family history suggestive of HS was available in only 16.6% of cases, whereas examination and investigations revealed HS in almost all families. Splenectomy was done in all symptomatic patients. In the 39 patients followed up for 1-9 years after splenectomy.

Adult↗